




IFW

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Dated: January 29, 2007

Signature:


(Arnold H. Krumholz)

Docket No.:
TEVIDR 3.0-108 CIP
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ábrahám et al.

Application No.: 10/771,847

Group Art Unit: 1624

Filed: February 3, 2004

Examiner: B. Kifle

For: NOVEL SUBSTITUTED 2,3-
BENZODIAZEPINE DERIVATIVES

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT AND
REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in Application No. 10/358,053, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p).

02/02/2007 HDEMESS1 00000054 121095 10771047

01 FC:1806 180.00 DA

Application No.: 10/771,847

Docket No.: TEVIDR 3.0-108 CIP

In the event that any additional fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: January 29, 2007

Respectfully submitted,

By 

Arnold H. Krumholz
Registration No.: 25,428
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

LD-459\



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|--------------------|
| Sheet | 1 | of | 3 | Attorney Docket Number | TEVIDR 3.0-108 CIP |
|-------|---|----|---|------------------------|--------------------|

Complete if Known

| | |
|------------------------|--------------------|
| Application Number | 10/771,847 |
| Filing Date | February 3, 2004 |
| First Named Inventor | Gizella Ábrahám |
| Art Unit | 1624 |
| Examiner Name | B. Kifle |
| Attorney Docket Number | TEVIDR 3.0-108 CIP |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | AA* | US-4,614,740 | 09-30-1986 | Lang et al. | |
| | AB* | US-5,536,832 | 07-16-1996 | Andrasi et al. | |
| | AC* | US-5,756,495 | 05-26-1998 | Hamori et al. | |
| | AD* | US-5,795,886 | 08-18-1998 | Anderson et al. | |
| | AE* | US-6,200,970 | 03-13-2001 | Ling et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | BA | EP-0 699 677 | 03/1996 | Lilly Co Eli | | |
| | BB | GB-2 311 779 | 10/1997 | Egyt Gyogyszervegyeszeti Gyar | | |
| | BC | WO-92/11262 | 07/1992 | Gyogyszerkutato Intezet | | |
| | BD | WO-95/01357 | 01/1995 | Gyogyszerkutato Intezet et al. | | |
| | BE | WO-96/04283 | 02/1996 | Schering Ag et al. | | |
| | BF | WO-96/06606 | 03/1996 | Lilly Co Eli et al. | | |
| | BG | WO-97/28135 | 08/1997 | Schering Ag et al. | | |
| | BH | WO-99/07707 | 02/1999 | Egyt Gyogyszervegyeszeti Gyar et al. | | |
| | BI | WO-99/07708 | 02/1999 | Egyt Gyogyszervegyeszeti Gyar et al. | | |
| | BJ | WO-01/04122 | 01/2001 | Egyt Gyogyszervegyeszeti Gyar et al. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-------------------|-----------------------|---|----------------|
| | CA | Anderson et al. (Bioorganic & Medicinal Chemistry Letters 9 (1999), 1953-1956).* | |
| | CB | Lipton et al., The New England Journal of Medicine 330, No. 9, pp. 613-622 (Mar. 3, 1994), published by the Massachusetts Medical Society, Boston, MA.. | |
| | CC | Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10.sup.th edition (2001), p. 309, published by the McGraw-Hill Companies, Inc., New York, New York.. | |
| | CD | Drugs of the Future 2001, 26(8), pp. 754-756 (2001), published by Prous Science, Barcelona, Spain.. | |
| | CE | Konitsiotis et al., Neurology 54, No. 8, pp. 1589-1595 (Apr. 25, 2000), published by Lippincott Williams & Wilkins, Philadelphia, PA.. | |
| | CF | Chase et al., J. Neurol. 247 [Suppl. 2]: pp. 11/36-11/42 (Apr. 2000), published by Steinkopff Verlag, Darmstadt, Germany.. | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|--------------------------|------------------|------------------------|--------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | | | |
| | | Application Number | 10/771,847 | | |
| | | Filing Date | February 3, 2004 | | |
| | | First Named Inventor | Gizella Ábrahám | | |
| | | Art Unit | 1624 | | |
| | | Examiner Name | B. Kifle | | |
| Sheet | 2 | of | 3 | Attorney Docket Number | TEVIDR 3.0-108 CIP |

| | |
|-----|---|
| CG | Belayev et al., Journal of Neurotrauma, vol. 18, No. 10, pp. 1031-1038, published by Mary Ann Liebert, Inc., Larchmont, NY, 2001.. |
| CH | Vorwerk et al., Survey of Ophthalmology, vol. 43, Supplement 1, pp. S142-S150 (Jun. 1999), published by Elsevier Science Inc., New York, New York.. |
| CI | Mattson et al., Nature, vol. 382, pp. 674-675 (Aug. 1996), published by Macmillan Magazines Ltd., London, England.. |
| CJ | Cacabelos et al., Drugs of Today 2000, 36(7), pp. 415-499 (2000), published by Prous Science, Barcelona, Spain.. |
| CK | Chappel et al., Neurology 58, No. 11, pp. 1680-1682 (Jun. 11, 2002), published by Lippincott Williams & Wilkins, Philadelphia, PA.. |
| CL | Rzeski et al., PNAS, vol. 98, No. 11, pp. 6372-6377 (May 22, 2001), published by the National Academy of Sciences, Washington, D.C.. |
| CM | Steinman, Nature Medicine, vol. 6, No. 1, pp. 15-16 (Jan. 2000), published by Nature Publishing Co., New York, New York.. |
| CN | Pitt et al., Nature Medicine, vol. 6, No. 1, pp. 67-70 (Jan. 2000) published by Nature Publishing Co., New York, New York.. |
| CO | Smith et al., Nature Medicine, vol. 6, No. 1, pp. 62-66 (Jan. 2000) published by Nature Publishing Co., New York, New York.. |
| CP | Akins et al., Current Medical Research and Opinions, vol. 18, Suppl. 2, pp. s9-s13 (2002), published by Libropharm Limited, Newbury, Berkshire UK.. |
| CQ | Buchan et al., Stroke 24, No. 12 [Suppl I]: I-148-I-152 (Dec. 1993), published by Lippincott Williams & Watkins, Baltimore, MD.. |
| CR | Mysbros et al., Annals New York Academy of Sciences, 765, 262-271 (1995), published by New York Academy of Sciences, New York, New York.. |
| CS | Parsons et al., Drug News Perspect. 11(9), 523-569 (1998), published by Prous Science, S.A., Barcelona, Spain.. |
| CT | Brauner-Osborne et al., J. Med. Chem., vol. 43, No. 14, 2609-2645 (2000), published by American Chemical Society, Washington, D.C.. |
| CU | Gill, Cerebrovascular and Brain Metabolism Reviews, 6, 225-256 (1994), published by Raven Press Publishers, New York, New York.. |
| CV | Meldrum, Neurology, 44, Suppl. 8, S14-S23 (1994), published by Advanstar Millennium, New York, New York.. |
| CW | Turski et al., J. Pharmacol. Exp. Ther., vol. 260, No. 2, 742-747 (1992), published by Williams & Wilkins, Baltimore, MD.. |
| CX | Skerry et al., Trends in Pharm. Sci., vol. 22, No. 4, 174-181 (2001), published by Elsevier Sciences London, London, UK.. |
| CY | Said, Trends in Pharm. Sci., vol. 20, 132-135 (1999), published by Elsevier Sciences London, London, UK.. |
| CZ | Said et al., Trends in Pharm. Sci., vol. 22, No. 7, 344-345 (2001), published by Elsevier Sciences London, London, UK.. |
| CA1 | Visi et al., CNS Drug Reviews, vol. 2, No. 1, 99-126 (1996), published by Neva Press, Inc., Branford, CT.. |
| CB1 | Tarnawa et al., European Journal of Pharmacology 167, 193-199 (1989), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.. |
| CC1 | Smith et al., European Journal of Pharmacology 187, 131-134 (1990), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.. |
| CD1 | Ouardouz et al., Neuroscience Letters 125, 5-8 (1991), published by Elsevier Scientific Publishers Ireland Ltd., Ireland.. |
| CE1 | Donevan et al., Neuron, 10, 51-59 (1993), published by Cell Press, 50 Church Street, Cambridge, Massachusetts.. |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

662543

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/771,847 |
| | | | | Filing Date | February 3, 2004 |
| | | | | First Named Inventor | Gizella Ábrahám |
| | | | | Art Unit | 1624 |
| | | | | Examiner Name | B. Kifle |
| Sheet | 3 | of | 3 | Attorney Docket Number | TEVIDR 3.0-108 CIP |

| | | | |
|--|-----|---|--|
| | CF1 | Smith et al., Nature Medicine, vol. 6, No. 1, 62-66 (2000), published by Nature America, Inc., New York, New York.. | |
| | CG1 | Nishizawa et al., Advances in Experimental Medicine and Biology, Vo. 462, Advances in Bladder Research, 275-281 (1999) published by Kluwer Academic/Plenum Publishers, New York, New York.. | |
| | CH1 | Bialer et al., Epilepsy Research, vol. 43, 11-58 (2001), published by Elsevier Science B.V., Amsterdam, The Netherlands.. | |
| | CI1 | Sheardown, Brain Research, 607, 189-194 (1993), published by Elsevier Science Publishers B.V., Amsterdam, The Netherlands.. | |
| | CJ1 | Bleakman et al., Neuropharmacology vol. 35, No. 12, 1689-1702 (1996), published by Pergamon, Elsevier Science Ltd., Kidlington, UK.. | |
| | CK1 | Upton, TiPS 15, 456-462 (1994), published by Elsevier Sciences, London, UK.. | |
| | CL1 | Randall et al., J. Pharmacol. Exp. Ther., 129, 163-171 (1960), published by Williams & Wilkins, Baltimore, MD.. | |
| | CM1 | Dunham et al., J. Am. Pharm. Assoc., vol. 46, No. 3, 208-209 (1957), published by the American Pharmaceutical Association, Washington, D.C.. | |
| | CN1 | Bartus et al., Stroke, vol. 25, No. 11, 2265-2270 (1994), published by American Heart Association, Dallas, Texas.. | |
| | CO1 | Sydserrff et al., British Journal of Pharmacology, vol. 114, 1631-1635 (1995), published by Stockton Press, New York, New York.. | |
| | CP1 | Steinman, Nature Medicine, vol. 6, No. 1, 15-16 (2000), published by Nature America Inc., New York, NY.. | |
| | CQ1 | Werner et al., J. Neurol. Transmiss. Suppl., 60, 375-385 (2000), published by Springer-Verlag/Wien, New York, New York.. | |
| | CR1 | Bjartmar et al., Drugs of Today 2002, 38(1), 17-29 (2002), published by Prous Science S.A., Barcelona, Spain.. | |
| | CS1 | Baker et al., Nature, vol. 404, 84-89 (2000), published by Nature Publishing Group, London, UK.. | |
| | CT1 | Gijbels et al., J. Clin. Invest. 94, 2177-2182 (1994), published by The Rockefeller University Press, New York, New York.. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

662543